Buscar
Chemomab Therapeutics Ltd
CMMBAñadir a la lista de seguimiento
2.270USD
+0.550+31.98%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
65.38MCap. mercado
13.03P/E TTM
Más Datos de Chemomab Therapeutics Ltd Compañía
Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Información de Chemomab Therapeutics Ltd
Símbolo de cotizaciónCMMB
Nombre de la empresaChemomab Therapeutics Ltd
Fecha de salida a bolsaAug 14, 2012
Director ejecutivoMor (Adi)
Número de empleados16
Tipo de seguridadDepository Receipt
Fin del año fiscalAug 14
DirecciónKiryat Atidim, Building 7
CiudadTEL AVIV-YAFO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIsrael
Código postal6158002
Teléfono972773310156
Sitio Webhttps://www.chemomab.com/
Símbolo de cotizaciónCMMB
Fecha de salida a bolsaAug 14, 2012
Director ejecutivoMor (Adi)
Ejecutivos de Chemomab Therapeutics Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
14.48K
+95.59%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Investor Relations
Investor Relations
--
--
Dr. David M. Weiner, M.D.
Dr. David M. Weiner, M.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
Mr. Jack Lawler
Mr. Jack Lawler
Chief Development Officer
Chief Development Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
14.48K
+95.59%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Chemomab Therapeutics Ltd?
Los cinco principales accionistas de Chemomab Therapeutics Ltd son: Ms. Sigal Fattal, CPA
¿Cuántas instituciones poseen acciones de Chemomab Therapeutics Ltd (CMMB)?
A fecha de 2026Q1, 33 instituciones poseen acciones de Chemomab Therapeutics Ltd, con un valor de mercado combinado de aproximadamente 402.96K, lo que representa el 5.60% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -450971.00.